Ⅵ-28胶囊辅助环磷酰胺治疗荷载LLC肿瘤小鼠的实验研究

Beneficial Effect of Vigconic VI-28 Capsule on Cyclophosphamide-Treated C57BL/6 Mice Carrying Lewis Lung Cancer Tumor

目的:研究复方中药VI-28胶囊(即卫康胶囊,主要成分有人参、鹿茸、菟丝子)辅助环磷酰胺体内抑制肿瘤生长的作用及其机制。方法:C57BL/6纯系小鼠背部皮下接种Lewis肺癌细胞(LCC,每只106个细胞),同时按40mg/kg隔天腹腔注射环磷酰胺治疗。实验组灌胃VI-28(2%悬液,每只0.5ml,隔天给药)。第28天时取小鼠胸腺和肿瘤组织块,计算肿瘤指数和胸腺指数。取脾细胞测定细胞免疫功能。组织切片观察所形成实体瘤的病理学特征。结果:小鼠接种LLC细胞14d后在接种部位开始形成实体瘤,瘤块直径增加为1—1.8cm。与单纯化疗荷瘤组小鼠相比,VI-28辅助治疗组的胸腺较大,脾细胞对ConA反应性较强,形成实体瘤的瘤块较小且分化程度较高。结论:VI-28胶囊可有效地促进化疗小鼠免疫功能的恢复,帮助化疗药物抑制肿瘤生长,是一种有效的化疗辅助药。

Objective: To investigate whether Vigconic VI-28 capsule, a formulated traditional Chinese medicine containing radix Ginseng, cornu cervi pantotrichum and semen cuscutae, can assist tumor chemotherapy in a mouse model. Methods: Female C57BL/6 mice were s. c. injected with viable Lewis lung cancer ( LLC) cells (106 cells/mouse) . The mice were then treated with cyclosposphamide (Cyp, 40 mg/kg bodyweight, once every other day). One group was intra-gastrically given 2% VI-28 (0.5 ml/mouse, every other day) during the course of the chemotherapy. By day 28, the mice were sacrificed and their thymic indices and tumor indices were calculated and compared. Splenocytes were collected for analysis of their immunological status. Histological study was carried to examine the solid tumors. Results: Fourteen days after the injection of LLC cells, solid tumors developed in most of the animals, reaching 1 ~ 1.8 cm diameters by 28 th day Compared with mice of the LCC + Cyp group, thymus glands from the LLC + Cyp + VI-28 group were significantly heavier. Splenocytes of the same group responded better to ConA stimulation in vitro. Histochemical examination of the tumor tissues revealed that tumors of the Cyp + VI-28 group were better differentiated (less aggressive) than that of the Cyp group. Conclusion: Vigconic VI-28 capsule can promote recovery of immune system in mice undergoing chemotherapy and help Cyp to control the growth of tumor cells in vivo.